Echinocandins

• 

  Subject Areas on Research

  • A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. 
  • A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. 
  • Advances in the treatment of invasive neonatal candidiasis. 
  • Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. 
  • Anidulafungin: a new echinocandin for the treatment of fungal infections. 
  • Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. 
  • Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. 
  • Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. 
  • Antifungal agents in children. 
  • Antifungal resistance: the clinical front. 
  • Antifungal serum concentration monitoring: an update. 
  • Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. 
  • Antifungal treatment in pediatric patients. 
  • Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. 
  • Breakthrough invasive candidiasis in patients on micafungin. 
  • Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. 
  • Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 
  • Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. 
  • Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. 
  • Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus. 
  • Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. 
  • Candida infective endocarditis: an observational cohort study with a focus on therapy. 
  • Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus. 
  • Caspofungin for invasive candidiasis at a tertiary care medical center. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Caspofungin-Mediated Growth Inhibition and Paradoxical Growth in Aspergillus fumigatus Involve Fungicidal Hyphal Tip Lysis Coupled with Regenerative Intrahyphal Growth and Dynamic Changes in β-1,3-Glucan Synthase Localization. 
  • Caspofungin: first approved agent in a new class of antifungals. 
  • Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. 
  • Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus. 
  • Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. 
  • Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. 
  • Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. 
  • Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. 
  • Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. 
  • Current options in antifungal pharmacotherapy. 
  • Determination of Echinocandin MICs for Candida species in less than 8 hours: comparison of the rapid susceptibility assay with the Clinical and Laboratory Standards Institute's broth microdilution assay. 
  • Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. 
  • Echinocandin pharmacodynamics: review and clinical implications. 
  • Echinocandins for the nursery: an update. 
  • Echinocandins: a wealth of choice--how clinically different are they? 
  • Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections. 
  • Echinocandins: role in antifungal therapy, 2005. 
  • Emerging echinocandins for treatment of invasive fungal infections. 
  • Engineering of New Pneumocandin Side-Chain Analogues from Glarea lozoyensis by Mutasynthesis and Evaluation of Their Antifungal Activity. 
  • Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. 
  • Evaluation of in vitro antifungal activity of LY121019. 
  • Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. 
  • Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. 
  • Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. 
  • Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus. 
  • Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. 
  • Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus. 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. 
  • In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. 
  • In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. 
  • Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. 
  • Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles. 
  • Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis. 
  • Micafungin: the US perspective. 
  • Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. 
  • Nebulizer delivery of micafungin aerosols. 
  • New facets of antifungal therapy. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Pediatric antifungal agents. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. 
  • Pharmacokinetics of an elevated dosage of micafungin in premature neonates. 
  • Pharmacokinetics of antifungal agents in children. 
  • Pharmacological resolution of a multiloculated Candida spp. liver abscess in a preterm neonate. 
  • Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. 
  • Population pharmacokinetics of micafungin in neonates and young infants. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Potential Microbiological Effects of Higher Dosing of Echinocandins. 
  • Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. 
  • Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. 
  • Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. 
  • Role of echinocandins in the management of fungal infections in neonates. 
  • Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. 
  • Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. 
  • Safety and pharmacokinetics of repeat-dose micafungin in young infants. 
  • Safety experience with caspofungin in pediatric patients. 
  • Safety of micafungin in infants: insights into optimal dosing. 
  • Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs. 
  • Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. 
  • Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 
  • The Aspergillus fumigatus P-type Golgi apparatus Ca2+/Mn2+ ATPase PmrA is involved in cation homeostasis and cell wall integrity but is not essential for pathogenesis. 
  • The chitin synthase genes chsA and chsC are not required for cell wall stress responses in the human pathogen Aspergillus fumigatus. 
  • The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. 
  • Timely Endocytosis of Cytokinetic Enzymes Prevents Premature Spindle Breakage during Mitotic Exit. 
  • Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus. 
  • Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. 
  • Treatment of experimental disseminated candidiasis with cilofungin. 
  • Treatment options for invasive fungal infections. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Juvvadi, Praveen Rao, Assistant Professor in Pediatrics, Pediatrics, Infectious Diseases